

Around the world in a month

PUERTO RICO
 The US FDA has convened a “hurricane shortages task force” after the US commonwealth’s pharma, biotech and medical device manufacturing was devastated by Hurricane Maria in September. The aim is to identify key issues and prioritize efforts to address medical product shortages.

PORTUGAL
 The Portuguese National Promotional Bank (IFD) launches a new fund focusing on investing in Portuguese life science companies. The fund is a joint effort between the IFD and Vesalius Biocapital of Luxembourg, and has garnered €65 (\$77) million of commitments as of May.

KENYA
 The National Biosafety Authority approves field-testing of *Xanthomonas*-wilt-disease-resistant bananas, laboratory and glasshouse trials for GM sweet potatoes, and National Performance Trials of GM maize, marking the first time that testing of biotech crops will occur in multiple locations in Kenya.

SWEDEN
 Researchers at Sweden’s Science for Life Laboratory present a new Human Pathology Atlas based on the analysis of 17 major cancer types, using data from 8,000 patients. They introduce a new concept for showing patient survival data called Interactive Survival Scatter plots by analyzing more than 2.5 petabytes of underlying publicly available data to generate more than 900,000 survival plots, describing the effects of RNA and protein levels on clinical survival.

UGANDA
 The Ugandan parliament passes a biotech law. The National Biosafety Act of 2017, a biotech law that allows scientists to move from confined trials at research stations to farmer field trials and tasting studies in advance of commercialization. Crops in development include bananas resistant to the devastating bacterial wilt, maize resistant to the stem borer and fall armyworm, and potatoes resistant to late blight.

© 2018 Nature America, Inc., part of Springer Nature. All rights reserved.

Map: © iStockphoto; Flags: Jelena Zanic/ Hemera/Thinkstock

PODCAST

First rounders: Stelios Papadopoulos

Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He’s the current chairman of the board at Biogen. His conversation with *Nature Biotechnology* touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late ’60s radicalism. <http://www.nature.com/nbt/podcast/index.html>



Corrections

In the July 2017 issue, in the article “Faster, deeper, smaller—the rise of antibody-like scaffolds,” it was incorrectly stated that Janssen’s fynomer drug for psoriasis was discontinued “when it induced rheumatoid arthritis”; in fact, it was discontinued “after it induced transient rashes and muscle pain.” In addition, it was stated that affibodies were invented by “a group led by Fredrik Frejd,” instead of “researchers at the Royal Institute of Technology, Stockholm, and Fredrik Frejd.” The errors were corrected in the HTML and PDF versions of the article on 9 August and 13 April 2018, respectively.

In the June 2017 issue, in Table 1 of the article “First deuterated drug approved,” the drug BMS-986165 was listed as a “deuterium-modified” version of rosuvastatin, rather than a “deuterium-modified” new molecular entity. The error was corrected in the html and pdf versions of the article on 13 April 2018.

Erratum: Corrections

Nat. Biotechnol. 35, 1004 (2017); published online 09 November 2017; corrected after print 13 April 2018

In the version of this correction notice initially published, the correction described in the first paragraph, second sentence, had not been made, nor had the correction in the second paragraph. Both corrections have been made as of 13 April 2018. The error has been corrected in the HTML and PDF versions of the article.